Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Memantine 20mg tablets
0411000G0AAADAD
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 258,410 |
|
Memantine 10mg tablets
0411000G0AAAAAA
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 140,482 |
|
Memantine 10mg/ml oral solution sugar free
0411000G0AAABAB
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 24,936 |
|
Memantine 20mg orodispersible tablets sugar free
0411000G0AAAGAG
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 7,392 |
|
Memantine 10mg orodispersible tablets sugar free
0411000G0AAAFAF
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 3,928 |
|
Memantine 5mg/10mg/15mg/20mg tabs treatment initiation pack
0411000G0AAAEAE
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 3,045 |
|
Memantine 5mg orodispersible tablets sugar free
0411000G0AAAKAK
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 1,631 |
|
Memantine 5mg/10mg/15mg/20mg orodispersible initiation pack
0411000G0AAAJAJ
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 217 |
|
Memantine 20mg soluble tablets sugar free
0411000G0AAAIAI
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 188 |
|
Memantine 10mg soluble tablets sugar free
0411000G0AAAHAH
|
Memantine hydrochloride (Dementia) | Memantine hydrochloride | Central Nervous System | 125 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.